X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Elder Pharma with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs CIPLA - Comparison Results

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA CIPLA ELDER PHARMA/
CIPLA
 
P/E (TTM) x -0.2 38.3 - View Chart
P/BV x 0.1 3.9 2.6% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 ELDER PHARMA   CIPLA
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
CIPLA
Mar-17
ELDER PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs380622 61.1%   
Low Rs188458 41.0%   
Sales per share (Unadj.) Rs491.2181.9 270.1%  
Earnings per share (Unadj.) Rs-3.212.9 -24.7%  
Cash flow per share (Unadj.) Rs14.429.3 49.2%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs376.5155.7 241.8%  
Shares outstanding (eoy) m20.54804.51 2.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.63.0 19.5%   
Avg P/E ratio x-89.342.0 -212.7%  
P/CF ratio (eoy) x19.718.4 107.0%  
Price / Book Value ratio x0.83.5 21.7%  
Dividend payout %015.5 0.0%   
Avg Mkt Cap Rs m5,833434,516 1.3%   
No. of employees `000NA23.0 0.0%   
Total wages/salary Rs m2,17926,338 8.3%   
Avg. sales/employee Rs ThNM6,349.1-  
Avg. wages/employee Rs ThNM1,143.0-  
Avg. net profit/employee Rs ThNM449.3-  
INCOME DATA
Net Sales Rs m10,089146,302 6.9%  
Other income Rs m2572,287 11.2%   
Total revenues Rs m10,346148,589 7.0%   
Gross profit Rs m-79224,758 -3.2%  
Depreciation Rs m36113,229 2.7%   
Interest Rs m2,7561,594 172.9%   
Profit before tax Rs m-3,65312,222 -29.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-70 0.0%   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m1251,798 7.0%   
Profit after tax Rs m-6510,354 -0.6%  
Gross profit margin %-7.816.9 -46.4%  
Effective tax rate %-3.414.7 -23.3%   
Net profit margin %-0.67.1 -9.2%  
BALANCE SHEET DATA
Current assets Rs m9,24087,370 10.6%   
Current liabilities Rs m9,99833,081 30.2%   
Net working cap to sales %-7.537.1 -20.2%  
Current ratio x0.92.6 35.0%  
Inventory Days Days4687 53.3%  
Debtors Days Days6062 96.2%  
Net fixed assets Rs m10,124111,567 9.1%   
Share capital Rs m2061,609 12.8%   
"Free" reserves Rs m5,582123,645 4.5%   
Net worth Rs m7,734125,254 6.2%   
Long term debt Rs m4,88936,454 13.4%   
Total assets Rs m22,882209,532 10.9%  
Interest coverage x-0.38.7 -3.8%   
Debt to equity ratio x0.60.3 217.2%  
Sales to assets ratio x0.40.7 63.1%   
Return on assets %11.85.7 206.2%  
Return on equity %-0.88.3 -10.2%  
Return on capital %22.38.5 262.5%  
Exports to sales %3.034.2 8.9%   
Imports to sales %0.48.3 5.1%   
Exports (fob) Rs m30750,050 0.6%   
Imports (cif) Rs m4312,203 0.4%   
Fx inflow Rs m30751,066 0.6%   
Fx outflow Rs m12517,678 0.7%   
Net fx Rs m18133,388 0.5%   
CASH FLOW
From Operations Rs m11,75423,824 49.3%  
From Investments Rs m-561-13,127 4.3%  
From Financial Activity Rs m-6,762-13,239 51.1%  
Net Cashflow Rs m4,432-2,478 -178.8%  

Share Holding

Indian Promoters % 39.6 16.0 247.5%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 7.5 12.2 61.5%  
FIIs % 16.8 23.7 70.9%  
ADR/GDR % 0.0 1.1 -  
Free float % 36.1 26.2 137.8%  
Shareholders   16,479 161,166 10.2%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   FDC LTD.  FULFORD INDIA  DR. REDDYS LAB  DIVIS LABORATORIES  UNICHEM LAB  

Compare ELDER PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day up 260 Points; Pharma Stocks Top Gainers(Closing)

After opening the day in red, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

CIPLA Announces Quarterly Results (4QFY18); Net Profit Down 347.8%

May 24, 2018 | Updated on May 24, 2018

For the quarter ended March 2018, CIPLA has posted a net profit of Rs 2 bn (down 347.8% YoY). Sales on the other hand came in at Rs 37 bn (up 3.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 5-YR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS